Abstract
A recent position statement issued by the UK National Osteoporosis Society recommends a triage approach to the use of peripheral dual-energy X-ray absorptiometry (pDXA) devices. Patients with a forearm T-score greater than –1 or less than –2.5 are regarded as normal or osteoporotic, respectively, while those with a T-score between –1 and –2.5 are sent for further assessment with spine and hip DXA. We have evaluated the NOS pDXA algorithm by comparing it with the alternative strategies of relying on forearm BMD alone, or performing spine and hip DXA in every patient. The evaluation was carried out using a mathematical model, and the predictions were compared with in vivo data obtained in patients referred for investigation by their general practitioner. In the model the population distribution of spine, hip, and forearm BMD was described by a trivariant Gaussian function. Relative risks of fracture were taken from a meta-analysis. The three strategies were compared using receiver operating characteristic (ROC) curves in which the percentage of future fracture cases identified was plotted against the percentage of the whole population found to have osteoporosis. ROC curves plotted for the discrimination of hip, vertebral, and Colles fracture risk and the risk of a fracture at any skeletal site were similar for all three strategies, with the curves for the NOS pDXA algorithm nearly identical to those for spine and hip DXA. For the case of hip fracture, vertebral fracture, or a fracture at any site, forearm BMD was slightly inferior to the NOS algorithm, but the reverse was true for Colles fracture. The small difference between the ROC curves suggests that forearm BMD used alone can reproduce clinical decision-making with the NOS pDXA algorithm provided that a T-score threshold of T=–2.1 is used for the diagnosis of osteoporosis, instead of the conventional figure of T=–2.5. Results from the in vivo study were in good agreement with the predictions of the model, although some differences were observed that were explained by inaccuracies in the forearm reference data. We conclude that use of forearm BMD alone with a modified T-score threshold of –2.1 would save the need for spine and hip DXA scans and identify only slightly fewer fracture cases for treatment.
Similar content being viewed by others
References
Cooper C, Campion G, Melton LJ (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289
Ray NF, Chan JK, Thamer M, Melton LJ (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24–35
Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D, on behalf of the European Foundation for Osteoporosis and Bone Disease (1997) Guidelines for diagnosis and treatment of osteoporosis. Osteoporos Int 7:390–406
Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541
Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: results from the Fracture Intervention Trial. JAMA 280:2077–2082
Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645
Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344–1352
Reginster J-Y, Minne HW, Sorensen OH et al (2000) Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91
Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118–4124
McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N Engl J Med 344:1434–1441
Delmas PD, Ensrud KE, Adachi JD et al (2001) Efficacy of raloxifene on vertebral fracture risk in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617
Royal College of Physicians (2000) Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. RCP, London
US Preventive Services Task Force (2002) Screening for osteoporosis in postmenopausal women: recommendations and rationale. Arch Intern Med 137:526–528
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259
WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series, No. 843. World Health Organization, Geneva
National Osteoporosis Society (2002) Position statement on the reporting of dual energy X-ray absorptiometry (DXA) bone mineral density scans. NOS, Bath, England
Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822
Miller PD, Siris ES, Barrett-Connor E et al (2002) Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res 17:2222–2230
Augat P, Fuerst T, Genant HK (1998) Quantitative bone mineral assessment at the forearm: a review. Osteoporos Int 8:299–310
Blake GM, Wahner HW, Fogelman I (1999) The evaluation of osteoporosis: dual energy x-ray absorptiometry and ultrasound in clinical practice. Martin Dunitz, London, pp 89–105
National Osteoporosis Society (2001) Position statement on the use of peripheral X-ray absorptiometry in the management of osteoporosis. NOS, Bath, England
Lu Y, Genant HK, Shepherd J et al (2001) Classification of osteoporosis based on bone mineral densities. J Bone Miner Res 16:901–910
Trumpler RJ, Weaver HF (1962) Statistical astronomy. Dover, New York, pp 42–68
Blake GM, Patel R, Knapp KM, Fogelman I (2003) Does the combination of two BMD measurements improve fracture discrimination? J Bone Miner Res 18:1955–1963
Blake GM, Fogelman I (2001) Peripheral or Central Densitometry: does it matter which we use? J Clin Densitom 4:83–96
Kelly TL (1990) Bone mineral density reference databases for American men and women. J Bone Miner Res 5[Suppl 2]:S249
Looker AC, Wahner HW, Dunn WL et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–489
Cooper C, Atkinson EJ, Jacobsen SJ et al (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiology 137:1001–1005
Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413
Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611–617
Torgerson DJ, Dolan P (2000) The cost of treating osteoporotic fractures in the United Kingdom female population (letter to the editor). Osteoporos Int 11:511–512
Grampp S, Genant HK, Mathur A et al (1997) Comparisons of non-invasive bone mineral measurements in assessing age-related bone loss, fracture discrimination and diagnostic classification. J Bone Miner Res 12:697–711
Faulkner KG, VonStetton E, Miller P (1999) Discordance in patient classification using T-scores. J Clin Densitom 2:343–350
Miller PD (2000) Controversies in bone mineral density diagnostic classifications. Calcif Tissue Int 66:317–319
Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: results from the Fracture Intervention Trial. JAMA 280:2077–2082
Bouxsein ML, Parker RA, Greenspan SL (1999) Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women. Osteoporos Int 10:505–509
Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrin Met 87(10):4528–4535
National Osteoporosis Society (2001) Position statement on the use of quantitative ultrasound in the management of osteoporosis. NOS, Bath, England
Blake GM, Fogelman I (1997) Interpretation of bone densitometry studies. Semin Nucl Med 27:248–260
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Patel, R., Blake, G.M. & Fogelman, I. An evaluation of the United Kingdom National Osteoporosis Society position statement on the use of peripheral dual-energy X-ray absorptiometry. Osteoporos Int 15, 497–504 (2004). https://doi.org/10.1007/s00198-003-1565-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-003-1565-2